These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37991858)

  • 61. sQUIZ your knowledge: Widespread millimetric papules in a patient with monoclonal gammopathy.
    Iglesias-Puzas Á; Rodríguez-Jato Q; Flórez Á
    Eur J Dermatol; 2019 Apr; 29(2):244-245. PubMed ID: 31106768
    [No Abstract]   [Full Text] [Related]  

  • 62. Clinical and histopathological improvement of scleromyxedema-induced microstomia after hyaluronidase injection.
    Akaslan TÇ; Yıldız P; Onsun N
    J Cosmet Dermatol; 2022 Oct; 21(10):4319-4322. PubMed ID: 35441782
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.
    Taha RY; Hasan S; Ibrahim F; Chantran Y; Sabah HE; Sivaraman S; Bozom IA; Sabbagh AA; Garderet L; Omri HE
    Medicine (Baltimore); 2020 Jul; 99(27):e20726. PubMed ID: 32629647
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Papular mucinosis associated with band acro-osteolysis: a new syndrome associated with connective tissue-disease.
    Teboul A; Gatfosse M; Senet P; Mariette X; Bagot M; Charvet E; Battistella M; Bouaziz JD; Mahévas T
    Rheumatology (Oxford); 2022 Mar; 61(3):e75-e76. PubMed ID: 34687298
    [No Abstract]   [Full Text] [Related]  

  • 65. Scleromyxedema in a patient with thyroid disease: an atypical case or a case for revised criteria?
    Hazan E; Griffin TD; Jabbour SA; Keller MS
    Cutis; 2020 Jan; 105(1):E6-E10. PubMed ID: 32074156
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
    Ataergin S; Arpaci F; Demiriz M; Ozet A
    Am J Clin Dermatol; 2008; 9(4):271-3. PubMed ID: 18572979
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).
    Blum M; Wigley FM; Hummers LK
    Medicine (Baltimore); 2008 Jan; 87(1):10-20. PubMed ID: 18204366
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.
    Bos R; de Waal EG; Kuiper H; Hazenberg BP; Vellenga E
    Rheumatology (Oxford); 2011 Oct; 50(10):1925-6. PubMed ID: 21719421
    [No Abstract]   [Full Text] [Related]  

  • 69. Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin.
    Mecoli CA; Talbot CC; Fava A; Cheadle C; Boin F; Wigley FM; Hummers LK
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):761-767. PubMed ID: 31008568
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Scleroderma mimics.
    Nashel J; Steen V
    Curr Rheumatol Rep; 2012 Feb; 14(1):39-46. PubMed ID: 22131103
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Resolution of Atypical Lichen Myxedematosus Following Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir-Velpatasvir Combination Therapy.
    Jones KM; Shelton ME; Soldano AC; Campbell J
    JAMA Dermatol; 2018 Sep; 154(9):1094-1096. PubMed ID: 30140911
    [No Abstract]   [Full Text] [Related]  

  • 72. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
    Baglama Š; Trčko K
    Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.
    Sroa N; Campbell S; Bechtel M
    J Drugs Dermatol; 2010 Mar; 9(3):263-5. PubMed ID: 20232589
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interstitial Granulomatous Variant of Scleromyxedema-A Diagnostic Pitfall.
    Long V; Tan W; Lee SSJ; Thng TGS
    Am J Dermatopathol; 2018 Apr; 40(4):279-282. PubMed ID: 28961556
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Scleromyxedema: a novel therapeutic approach.
    El-Darouti MA; Hegazy RA; Fawzy MM; Mahmoud SB; Dorgham DA
    J Am Acad Dermatol; 2013 Dec; 69(6):1062-6. PubMed ID: 24238173
    [No Abstract]   [Full Text] [Related]  

  • 76. Acral lichen myxedematosus showing acro-osteolysis in a patient with Sjögren syndrome.
    Satoh M; Yamamoto T
    J Dermatol; 2021 Apr; 48(4):e173-e174. PubMed ID: 33560548
    [No Abstract]   [Full Text] [Related]  

  • 77. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
    Efthimiou P; Blanco M
    Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Scleromyxedema (papular mucinosis) with dermato-neuro syndrome: a rare, potentially fatal complication.
    Landais AF; Duchemin CM; Bourhis VM
    Presse Med; 2015; 44(7-8):850-1. PubMed ID: 26051450
    [No Abstract]   [Full Text] [Related]  

  • 79. Cardiomyopathy in scleromyxedema: report of a fatal case.
    De Simone C; Castriota M; Carbone A; Marini Bettolo P; Pieroni M; Rongioletti F
    Eur J Dermatol; 2010; 20(6):852-3. PubMed ID: 20977988
    [No Abstract]   [Full Text] [Related]  

  • 80. [Scleromyxedema as a systemic disease of glycosaminoglycan accumulation].
    Radenska-Lopovok SG; Volkova P; Gorodetsky VR; Egorova ON; Ananyeva LP
    Arkh Patol; 2018; 80(3):53-58. PubMed ID: 29927441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.